Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-11-06

FDA Approved: BRYHALI — Original Application (Bausch Health US, LLC)

View source ↗

Summary

FDA approved Bryhali, the brand-name halobetasol propionate topical product, under an original NDA by Bausch Health US, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BRYHALI (HALOBETASOL PROPIONATE)

Snippet

ORIG AP for BRYHALI (HALOBETASOL PROPIONATE)